Please login to the form below

Not currently logged in
Email:
Password:

oral GLP-1 drug

This page shows the latest oral GLP-1 drug news and features for those working in and with pharma, biotech and healthcare.

Novo Nordisk set to acquire Emisphere Technology for $1.8bn

Novo Nordisk set to acquire Emisphere Technology for $1.8bn

Novo won US Food and Drug Administration (FDA) approval for Rybelsus in September 2019, when it became the first oral alternative to injectable GLP-1 agonists. ... The two companies first teamed up in 2007 when Novo signed an initial licence agreement

Latest news

  • Lilly’s Trulicity scores CV reduction indication in the US Lilly’s Trulicity scores CV reduction indication in the US

    The new MACE approval could help Lilly in its fight for market share with other GLP-1 agonists, including Novo Nordisk’s once-weekly drug Ozempic (semaglutide). ... Novo also has Rybelsus – oral semaglutide – in its arsenal, and analysts at Pareto

  • Novo Nordisk preps for speedy oral GLP-1 drug filing Novo Nordisk preps for speedy oral GLP-1 drug filing

    Despite that competition Novo’s older GLP-1 drug Victoza (liraglutide) – given as a daily injection – held up remarkably well in 2018, with sales up 5% to 24.3bn krone, while ... Oral semaglutide is seen as critical to Novo’s hopes of maintaining

More from news
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Oral biologics delivery still elusive Oral biologics delivery still elusive

    market. Some peptides - such as transplant rejection drug cyclosporine and diuretic hormone desmopressin acetate - are simple enough to be amenable to standard oral formulation technologies and so have been available for ... Oramed - whose technology

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Valid Insight

Valid Insight is an award-winning pharmaceutical global market access consultancy....

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics